← Back to Search

Other

Caffeine-based Cream for Breast Cancer (ReDCoAT Trial)

Phase 2
Waitlist Available
Led By Naamit Kurshan Gerber
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient will receive irradiation of the chest wall
Patient has histologically-confirmed carcinoma of breast (all subtypes are permitted)
Must not have
Patient has (cT4b-d) unhealed wound in the radiation field
Planned accelerated or hypofractionated fractionation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years

Summary

This trial is testing a caffeine-based cream to see if it can help reduce problems after breast reconstruction surgery in patients who need radiation therapy. The cream is compared to another cream to check its effectiveness.

Who is the study for?
This trial is for breast cancer patients who've had a mastectomy with tissue expander reconstruction and need post-mastectomy radiation. They must not be pregnant, have no previous chest radiation, or concurrent chemo (except hormonal therapy or Trastuzumab). Those with inflammatory breast cancer, unhealed wounds in the radiation field, caffeine allergy, lupus, or scleroderma are excluded.
What is being tested?
The study tests if a caffeine-based antifibrosis cream can lower reconstructive complications from radiation therapy compared to a placebo. Participants will apply either the caffeine cream or placebo to their chest wall during their treatment period.
What are the potential side effects?
Potential side effects may include skin reactions related to the application of the cream such as redness, itching, or rash. Since it's topical and contains caffeine, there might also be local irritation or allergic responses in those sensitive to ingredients.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I will undergo chest wall radiation therapy.
Select...
I have been diagnosed with breast cancer.
Select...
I had a mastectomy with temporary expanders and need radiation, but don't have inflammatory breast cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an unhealed wound in the area treated with radiation.
Select...
I am scheduled for a fast or intense course of radiation therapy.
Select...
I won't need extra radiation doses as they could affect the study's main outcome.
Select...
I have had radiation therapy on the same side of my chest before.
Select...
I am not pregnant, as confirmed by a urine test.
Select...
I have skin changes or inflammation in my breast.
Select...
I have lupus or scleroderma, which could worsen skin reactions to radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Standard Toxicity Scoring

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Caffeine Based CreamExperimental Treatment1 Intervention
caffeine based cream during and for 4 weeks following radiation
Group II: PlaceboPlacebo Group1 Intervention
placebo cream during and for 4 weeks following radiation

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for breast cancer include surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Surgery and radiation aim to remove or destroy cancer cells locally. Chemotherapy uses drugs to kill rapidly dividing cells throughout the body. Hormone therapy blocks hormones like estrogen that fuel certain breast cancers. Targeted therapies, such as trastuzumab, specifically attack cancer cells with certain markers, minimizing damage to normal cells. The caffeine-based cream being studied leverages caffeine's anti-inflammatory and antioxidant properties to potentially reduce complications from radiation therapy. These mechanisms are crucial as they aim to improve treatment efficacy while minimizing side effects, enhancing the overall quality of life for breast cancer patients.
Effects of botanical drugs in the treatment of cancer-related fatigue in patients with gastric cancer: A meta-analysis and prediction of potential pharmacological mechanisms.UVB and caffeine: inhibiting the DNA damage response to protect against the adverse effects of UVB.

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,408 Previous Clinical Trials
855,725 Total Patients Enrolled
38 Trials studying Breast Cancer
7,424 Patients Enrolled for Breast Cancer
Naamit Kurshan GerberPrincipal InvestigatorNYU Langone Medical Center

Media Library

Caffeine anhydrous 5% added to Lipoderm Cream Base (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03768492 — Phase 2
Breast Cancer Research Study Groups: Caffeine Based Cream, Placebo
Breast Cancer Clinical Trial 2023: Caffeine anhydrous 5% added to Lipoderm Cream Base Highlights & Side Effects. Trial Name: NCT03768492 — Phase 2
Caffeine anhydrous 5% added to Lipoderm Cream Base (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03768492 — Phase 2
~11 spots leftby Dec 2025